Connection

GUILLERMO GARCIA-MANERO to Gene Expression Regulation, Neoplastic

This is a "connection" page, showing publications GUILLERMO GARCIA-MANERO has written about Gene Expression Regulation, Neoplastic.
  1. Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia. Leuk Res. 2021 02; 101:106511.
    View in: PubMed
    Score: 0.251
  2. Down-regulation of EZH2 expression in myelodysplastic syndromes. Leuk Res. 2016 May; 44:1-7.
    View in: PubMed
    Score: 0.179
  3. Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Leuk Res. 2005 Jul; 29(7):739-48.
    View in: PubMed
    Score: 0.083
  4. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol. 2021 07 01; 96(7):E246-E249.
    View in: PubMed
    Score: 0.064
  5. Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res. 2018 10; 73:78-85.
    View in: PubMed
    Score: 0.053
  6. Oncogenic functions of the transcription factor Nrf2. Free Radic Biol Med. 2013 Dec; 65:750-764.
    View in: PubMed
    Score: 0.037
  7. Histone methylation in myelodysplastic syndromes. Epigenomics. 2011 Apr; 3(2):193-205.
    View in: PubMed
    Score: 0.032
  8. Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA. Am J Hematol. 2011 Feb; 86(2):237-8.
    View in: PubMed
    Score: 0.032
  9. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound ?-phenylethyl isothiocyanate. Blood. 2010 Oct 14; 116(15):2732-41.
    View in: PubMed
    Score: 0.030
  10. Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias. Genes Chromosomes Cancer. 2010 Feb; 49(2):182-91.
    View in: PubMed
    Score: 0.029
  11. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009 Jun 18; 113(25):6330-7.
    View in: PubMed
    Score: 0.027
  12. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008 Feb 01; 111(3):1060-6.
    View in: PubMed
    Score: 0.025
  13. Differential tumor suppressor properties and transforming growth factor-beta responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation. Oncogene. 2007 Mar 01; 26(10):1439-48.
    View in: PubMed
    Score: 0.023
  14. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res. 2013 Sep; 23(9):1446-61.
    View in: PubMed
    Score: 0.009
  15. EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion. Neuro Oncol. 2012 Sep; 14(9):1125-35.
    View in: PubMed
    Score: 0.009
  16. Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells. J Cell Mol Med. 2010 Jun; 14(6B):1777-92.
    View in: PubMed
    Score: 0.007
  17. Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia. Leuk Res. 2009 Oct; 33(10):1361-6.
    View in: PubMed
    Score: 0.007
  18. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer. 2008 Feb 15; 112(4):837-45.
    View in: PubMed
    Score: 0.006
  19. Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers. Cancer Res. 2004 Apr 01; 64(7):2411-7.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.